CHOLOGRAFIN MEGLUMINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOGRAFIN MEGLUMINE is an injectable diagnostic contrast agent developed by Bracco, approved in 1954 for radiographic imaging procedures. It is an iodinated organic compound used to enhance visualization of the biliary system and related structures during imaging studies. The drug works by absorbing X-rays to create contrast in targeted anatomical regions.
LOE Approaching
This legacy diagnostic product faces moderate competitive pressure (30/100) with diminishing commercial momentum, indicating a stable but contracting team structure focused on managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CHOLOGRAFIN MEGLUMINE offers limited career advancement potential given the product's LOE approaching status and minimal job openings. Roles are primarily focused on portfolio management, customer retention, and regulatory maintenance rather than innovation or expansion.
Regional Sales ManagerProduct Manager
Worked on CHOLOGRAFIN MEGLUMINE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.